Approximately 40% of cancer-related clinical trials terminate prematurely, 1 which results in an immense loss of time, money, and human effort. Failure to optimize clinical trial design, inefficient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback